Literature DB >> 28503424

Interleukin-13 and age-related macular degeneration.

Bo Fu1, Zhe-Li Liu1, Han Zhang2, Feng Gu2.   

Abstract

AIM: o identify the effects of interleukin (IL)-13 on retinal pigment epithelial (RPE) cells and the IL-13 level in aqueous humor of age-related macular degeneration (AMD) patients.
METHODS: IL-13 levels in aqueous humor specimens from AMD patients were detected with enzyme-linked immunosorbent assay (ELISA). ARPE-19 cells were treated with 10 ng/mL IL-13 for 12, 24, and 48h. The cell proliferaton was evaluated by the MTS method. The mRNA and protein levels of α-SMA and ZO-1 were evaluated with quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot respectively. The expression of tumor necrosis factor-α (TNF-α), transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF) were assessed by ELISA.
RESULTS: IL-13 levels in the aqueous humor of patients with AMD were significantly higher than those in the control (167.33±17.64 vs 27.12±5.65 pg/mL; P<0.01). In vitro, IL-13 of high concentrations (10, 15, and 20 ng/mL) inhibited ARPE-19 cell proliferation. α-SMA mRNA in ARPE-19 cell were increased (1.017±0.112 vs 1.476±0.168; P<0.001) and ZO-1 decreased (1.051±0.136 vs 0.702±0.069; P<0.001) after treated with 10 ng/mL IL-13 for 48h. The protein expression of α-SMA and ZO-1 also showed the same tendency (α-SMA: P=0.038; ZO-1: P=0.008). IL-13 significantly reduced the level of TNF-α (44.70±1.67 vs 31.79±3.53 pg/mL; P=0.005) at 48h, but the level of TGF-β2 was significantly increased from 34.44±2.92 to 57.61±6.31 pg/mL at 24h (P=0.004) and from 61.26±1.11 to 86.91±3.59 pg/mL at 48h (P<0.001). While expressions of VEGF didn't change after IL-13 treatment.
CONCLUSION: IL-13 in vitro inhibit ARPE-19 cell proliferation and expression in the aqueous may be associated with AMD.

Entities:  

Keywords:  age-related macular degeneration; interleukin-13; retinal pigment epithelial cell

Year:  2017        PMID: 28503424      PMCID: PMC5406629          DOI: 10.18240/ijo.2017.04.06

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  36 in total

1.  Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration.

Authors:  Agnes Boltz; Manuel Ruiß; Jost B Jonas; Yong Tao; Florian Rensch; Martin Weger; Gerhard Garhöfer; Sophie Frantal; Yosuf El-Shabrawi; Leopold Schmetterer
Journal:  Ophthalmology       Date:  2012-04-21       Impact factor: 12.079

Review 2.  Innate immunity and inflammation in systemic sclerosis.

Authors:  Robert Lafyatis; Michael York
Journal:  Curr Opin Rheumatol       Date:  2009-11       Impact factor: 5.006

3.  Isoform-specific changes in scleral transforming growth factor-beta expression and the regulation of collagen synthesis during myopia progression.

Authors:  Andrew I Jobling; Martin Nguyen; Alex Gentle; Neville A McBrien
Journal:  J Biol Chem       Date:  2004-01-28       Impact factor: 5.157

4.  Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis.

Authors:  Patrizia Fuschiotti; Thomas A Medsger; Penelope A Morel
Journal:  Arthritis Rheum       Date:  2009-04

5.  IL-13 induces YY1 through the AKT pathway in lung fibroblasts.

Authors:  Jia Guo; Hongwei Yao; Xin Lin; Haodong Xu; David Dean; Zhou Zhu; Gang Liu; Patricia Sime
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

6.  Choroidal neovascularization regression on fluorescein angiography after VEGF blockade.

Authors:  Diana V Do; Lark Greenwald; Mohamed Ibrahim; Yasir Sepah; Quan Dong Nguyen
Journal:  Case Rep Ophthalmol       Date:  2012-11-07

7.  Association of IL13R alpha 1 +1398A/G polymorphism in a North Indian population with asthma: A case-control study.

Authors:  Shweta Sinha; Jagtar Singh; Surinder Kumar Jindal; Niti Birbian
Journal:  Allergy Rhinol (Providence)       Date:  2015-01

Review 8.  Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?

Authors:  Michael W Stewart
Journal:  J Clin Med       Date:  2015-05-21       Impact factor: 4.241

9.  The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab.

Authors:  Ozlem Dikmetas; Sibel Kadayıfcılar; Bora Eldem
Journal:  Mol Vis       Date:  2013-12-20       Impact factor: 2.367

10.  TNF-α-induced ICAM-1 expression and monocyte adhesion in human RPE cells is mediated in part through autocrine VEGF stimulation.

Authors:  Peeradech Thichanpiang; Steven J Harper; Kanokpan Wongprasert; David O Bates
Journal:  Mol Vis       Date:  2014-06-10       Impact factor: 2.367

View more
  4 in total

1.  Effect of Humanin G (HNG) on inflammation in age-related macular degeneration (AMD).

Authors:  Sonali Nashine; Pinchas Cohen; Junxiang Wan; M Cristina Kenney
Journal:  Aging (Albany NY)       Date:  2022-05-16       Impact factor: 5.955

2.  LXRs regulate features of age-related macular degeneration and may be a potential therapeutic target.

Authors:  Mayur Choudhary; Ebraheim N Ismail; Pei-Li Yao; Faryan Tayyari; Roxana A Radu; Steven Nusinowitz; Michael E Boulton; Rajendra S Apte; Jeffrey W Ruberti; James T Handa; Peter Tontonoz; Goldis Malek
Journal:  JCI Insight       Date:  2020-01-16

Review 3.  The Role of Inflammation in Age-Related Macular Degeneration.

Authors:  Wei Tan; Jingling Zou; Shigeo Yoshida; Bing Jiang; Yedi Zhou
Journal:  Int J Biol Sci       Date:  2020-09-23       Impact factor: 6.580

4.  Extracellular vesicles released by human retinal pigment epithelium mediate increased polarised secretion of drusen proteins in response to AMD stressors.

Authors:  Miguel Flores-Bellver; Jason Mighty; Silvia Aparicio-Domingo; Kang V Li; Cui Shi; Jing Zhou; Hannah Cobb; Patrick McGrath; German Michelis; Patricia Lenhart; Ganna Bilousova; Søren Heissel; Michael J Rudy; Christina Coughlan; Andrew E Goodspeed; S Patricia Becerra; Stephen Redenti; M Valeria Canto-Soler
Journal:  J Extracell Vesicles       Date:  2021-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.